Back
Compare AU
Compare HQLT vs. CURE
Compare shares and ETFs on the ASX that you can trade on Pearler.
Overview
When it comes to investing in the Australian stock market, Exchange-Traded Funds (ETFs) are a popular choice. Two well-known options in the Australian Securities Exchange (ASX) are the Betashares Global Quality Leaders Currency Hedged ETF (HQLT) and the Global X S&P Biotech ETF (CURE). In this comparison, we'll delve into these ETFs across various dimensions to help you make an informed investment decision.
Community Stats
HQLT | CURE | |
|---|---|---|
Popularity | Low | Low |
Pearlers invested | 8 | 74 |
Median incremental investment | $6,023.50 | $652.50 |
Median investment frequency | Monthly | Monthly |
Median total investment | $8,760.33 | $1,350.67 |
Average age group | > 35 | > 35 |
Key Summary
HQLT | CURE | |
|---|---|---|
Strategy | HQLT.AX was created on 2020-06-05 by BetaShares. The fund's investment portfolio concentrates primarily on total market equity. The investment objective of the Fund is to provide an investment return that aims to track the performance of the iSTOXX MUTB Global ex-Australia Quality Leaders Index AUD Hedged (the “Index”), before taking into account fees and expenses. | CURE.AX was created on 2018-11-08 by Global X. The fund's investment portfolio concentrates primarily on health care equity. The Fund aims to provide investors with a return that (before fees and expenses) tracks the performance of the S&P Biotechnology Select Industry Index. |
Top 3 holdings | NZD - NEW ZEALAND DOLLAR (0 %) NETFLIX INC (2.45 %) INTUIT INC (2.37 %) | Exact Sciences Corp (3.23 %) Alnylam Pharmaceuticals Inc (3.16 %) Neurocrine Biosciences Inc (2.89 %) |
Top 3 industries | Other (34.40 %) Information Technology (27.81 %) Industrials (10.65 %) | Health Care (100.00 %) Other (10.24 %) |
Top 3 countries | United States (67.90 %) Japan (10.44 %) Switzerland (4.83 %) | United States (97.17 %) Switzerland (1.51 %) United Kingdom of Great Britain and Northern Ireland (1.16 %) |
Management fee | 0.38 % | 0.45 % |
Key Summary
HQLT | CURE | |
|---|---|---|
Issuer | BetaShares | Global X |
Tracking index | iSTOXX MUTB Global ex-Australia Quality Leaders Index - AUD | S&P Biotechnology Select Industry |
Asset class | ETF | ETF |
Management fee | 0.38 % | 0.45 % |
Price | $31.01 | $43.57 |
Size | $106.441 million | $29.574 million |
10Y return | N/A | N/A |
Annual distribution yield (5Y) | 2.02 % | 4.24 % |
Market | ASX | ASX |
First listed date | 09/06/2020 | 12/11/2018 |
Purchase fee | $6.50 | $6.50 |
Community Stats
HQLT | CURE | |
|---|---|---|
Popularity | Low | Low |
Pearlers invested | 8 | 74 |
Median incremental investment | $6,023.50 | $652.50 |
Median investment frequency | Monthly | Monthly |
Median total investment | $8,760.33 | $1,350.67 |
Average age group | > 35 | > 35 |
Pros and Cons
HQLT | CURE | |
|---|---|---|
Pros |
|
|
Cons |
|
|
HQLT | CURE |
|---|---|
Lower exposure to US market | Higher exposure to US market |
Lower management fee | Higher management fee |
Higher price growth | Lower price growth |
Lower distribution yield | Higher distribution yield |